Theranostics in Hematooncology

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe novel and already established radiopharmaceuticals for treatment of hematologic neoplasms such as leukemia or lymphoma; (2) explain why small molecules specifically binding to C-X-C motif chemokine receptor 4 may serve as theranostic agents, particularly for hematologic applications; and (3) describe advantages and disadvantages of lymphoma treatment using radioimmunoconjugates. Financial Disclosure: Dr. Buck has received speaker honoraria from Novartis/AAA and PentixaPharm, is a board member/officer/trustee for PentixaPharm, and is involved in [68Ga]Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm. Dr. Werner has received speaker honoraria from Novartis/AAA and PentixaPharm, reports advisory board work for Novartis/AAA and Bayer, has received funding from the German Research Foundation (453989101, 507803309), and is involved in [68Ga]Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm. Dr. Higuchi has received funding from the German Research Foundation (453989101). Dr. Rasche reports support from, isa consultant/advisor to, and is a meeting participant/lecturer for BMS, GSK, Pfizer, Janssen, and Amgen. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through July 2026.

Automated summary

This article discusses the novel and established radiopharmaceuticals used for treating hematologic neoplasms, the use of small molecules specifically binding to C-X-C motif chemokine receptor 4 as theranostic agents, and the advantages and disadvantages of lymphoma treatment using radioimmunoconjugates.